Literature DB >> 18533230

Decreased bladder cancer growth in parous mice.

Aimee M Johnson1, Mary J O'Connell, Edward M Messing, Jay E Reeder.   

Abstract

OBJECTIVES: To investigate the association between parity and exophytic bladder cancer growth in the UPII-SV40T transgenic mouse model of bladder cancer.
METHODS: The UPII-SV40T transgenic mice express the simian virus 40 large T antigen specifically in the urothelium (driven by uroplakin II promoter) and reliably develop bladder cancer. UPII-SV40T transgenic female mice were either never bred (nulliparous; n = 6) or placed in breeding pairs and allowed full-term pregnancies and lactation. Multiparous animals (n = 5) had between 2 and 4 litters. UPII-SV40T transgenic male mice were sham-operated (intact; n = 9) or castrated (n = 8) at 24 weeks of age. Noninvasive, contrast-enhanced, flat panel detector-based, cone beam computed tomographic imaging of animals at 32 weeks of age permitted quantification of bladder cancer volumes.
RESULTS: Multiparous animals had significantly smaller bladder cancers than their nulliparous female (P < .001) and intact male (P = .007) counterparts but not different from castrated males. Bladder cancer volume in nulliparous females was significantly larger than castrated males (P < .001) but not different from intact males.
CONCLUSIONS: These results suggest that pregnancy, parity, lactation, or a combination of these may play a protective role in bladder cancer by inhibiting tumor growth. This could be an important model system for studying the effects of pregnancy/lactation hormones on bladder cancer, which could lead to identification of additional risk factors of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18533230     DOI: 10.1016/j.urology.2008.04.028

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  16 in total

1.  Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology.

Authors:  Carol A Davis-Dao; Katherine D Henderson; Jane Sullivan-Halley; Huiyan Ma; Dee West; Yong-Bing Xiang; Manuela Gago-Dominguez; Mariana C Stern; J Esteban Castelao; David V Conti; Malcolm C Pike; Leslie Bernstein; Victoria K Cortessis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-14       Impact factor: 4.254

2.  Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract.

Authors:  Eiji Kashiwagi; Kazutoshi Fujita; Seiji Yamaguchi; Hiroaki Fushimi; Hiroki Ide; Satoshi Inoue; Taichi Mizushima; Leonardo O Reis; Rajni Sharma; George J Netto; Norio Nonomura; Hiroshi Miyamoto
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

Review 3.  Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.

Authors:  Andrea B Apolo; Vanessa Hoffman; Matthew G Kaag; David M Latini; Cheryl T Lee; Jonathan E Rosenberg; Margaret Knowles; Dan Theodorescu; Bogdan A Czerniak; Jason A Efstathiou; Matthew L Albert; Srikala S Sridhar; Vitaly Margulis; Surena F Matin; Matthew D Galsky; Donna Hansel; Ashish M Kamat; Thomas W Flaig; Angela B Smith; Edward Messing; Diane Zipursky Quale; Yair Lotan
Journal:  Urol Oncol       Date:  2014-07-25       Impact factor: 3.498

4.  Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.

Authors:  Venkateshwar Madka; Altaf Mohammed; Qian Li; Yuting Zhang; Jagan M R Patlolla; Laura Biddick; Stan Lightfoot; Xue-Ru Wu; Vernon Steele; Levy Kopelovich; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-02

5.  TP53 modulating agent, CP-31398 enhances antitumor effects of ODC inhibitor in mouse model of urinary bladder transitional cell carcinoma.

Authors:  Venkateshwar Madka; Altaf Mohammed; Qian Li; Yuting Zhang; Gaurav Kumar; Stan Lightfoot; Xueru Wu; Vernon Steele; Levy Kopelovich; Chinthalapally V Rao
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

6.  p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.

Authors:  Venkateshwar Madka; Yuting Zhang; Qian Li; Altaf Mohammed; Puneet Sindhwani; Stan Lightfoot; Xue-Re Wu; Levy Kopelovich; Chinthalapally V Rao
Journal:  Neoplasia       Date:  2013-08       Impact factor: 5.715

7.  Differential expression of cytokeratin 14 and 18 in bladder cancer tumorigenesis.

Authors:  Yun-Peng Li; Xiao-Peng Jia; Yu-Qing Jiang; Wei Wang; Yun-Liang Wang; Xiu-Li Wang; Yue-Xian Guo
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-19

8.  Significant cancer prevention factor extraction: an association rule discovery approach.

Authors:  Jesmin Nahar; Kevin S Tickle; A B M Shawkat Ali; Yi-Ping Phoebe Chen
Journal:  J Med Syst       Date:  2009-10-03       Impact factor: 4.460

Review 9.  Fetal microchimerism and cancer.

Authors:  Janet A Sawicki
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

10.  Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen.

Authors:  Suraj Konnath George; Veronica Tovar-Sepulveda; Steven S Shen; Weiguo Jian; Yiqun Zhang; Susan G Hilsenbeck; Seth P Lerner; Carolyn L Smith
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.